A randomised, double-blind, placebo controlled study of cobiprostone in patients with proton pump inhibitor (PPI)-refractory non-erosive reflux disease (NERD) or symptomatic gastroesophageal reflux disease (sGERD)

Trial Profile

A randomised, double-blind, placebo controlled study of cobiprostone in patients with proton pump inhibitor (PPI)-refractory non-erosive reflux disease (NERD) or symptomatic gastroesophageal reflux disease (sGERD)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Cobiprostone (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Therapeutic Use
  • Sponsors Sucampo Pharmaceuticals
  • Most Recent Events

    • 19 Apr 2016 Status changed from recruiting to discontinued, as the efficacy data from the top-line results did not demonstrate significant benefit; according to a Sucampo Pharmaceuticals media release.
    • 19 Apr 2016 Primary endpoint has not been met (Improvement in heartburn symptoms as determined by patient reported outcomes), as reported in a Sucampo Pharmaceuticals media release.
    • 19 Apr 2016 Top-line results published in the Sucampo Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top